Join us
If you believe in the power of what science can do, join us in our endeavour to push the boundaries of science to deliver life-changing medicines.
Bicycles are being investigated in a number of ways and disease areas, including as cytotoxic targeting agents (Bicycle® Toxin Conjugates, or BTCs) where a tumor-targeting Bicycle is linked to a toxin payload to form a drug conjugate.1 The tumor-targeted Bicycle directs the payload to the specific cell or tissue for release and targeted therapeutic response.
Bicycles can also be joined with each other to form higher order structures such as tandems, trimers, and tetramers, allowing them to engage targets and target classes inaccessible to traditional small molecules or to engage multiple drug targets or cell types simultaneously.
Bicycles are a new modality that have the potential to become part of the next generation of therapeutics, combining specificity, potency, and attractive drug-like properties. In collaboration with Bicycle Therapeutics, we are developing Bicycle-based molecules against a wide range of drug targets in two of our therapy areas, Respiratory & Immunology and Cardiovascular, Renal and Metabolism.
With the versatility and molecular specificity of bicyclic peptides, our aim is to rapidly investigate drug targets in several indications across our therapeutic areas.
If you believe in the power of what science can do, join us in our endeavour to push the boundaries of science to deliver life-changing medicines.
We know that however innovative our science, however effective our medicines and delivery, to achieve all we want to achieve, we cannot do it alone.
Veeva ID: Z4-46778
Date of preparation: August 2022